title: [A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
abstract: Sixty-four patients with active acromegaly and three patients with gigantism were treated with the long acting somatostatin analog SMS 201-995 (50-500 micrograms, sc, every 6-12 h or 150-880 micrograms daily by intermittent sc infusion, for up to 114 weeks). The fasting plasma GH levels were significantly suppressed (less than 50% of the values before treatment) in 49 patients and became normal in 18 patients. Suppression of GH secretion was associated with normalization of plasma somatomedin-C levels (14 out of 30 cases) and significant clinical improvement such as disappearance of headache and decrease of excessive sweating. Shrinkage of pituitary tumors as determined by computed tomography and/or magnetic resonance imaging studies occurred in 11 out of 40 cases. Side effects were minimal and tolerable. SMS 201-995 appears to be an effective agent for the treatment of acromegaly and gigantism.
authors.affiliation: Department of Medicine, Kyoto University Faculty of Medicine.
authors.forename: A
authors.initials: A
authors.lastname: Shimatsu
authors.forename: H
authors.initials: H
authors.lastname: Imura
authors.forename: M
authors.initials: M
authors.lastname: Irie
authors.forename: S
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Goto
authors.forename: N
authors.initials: N
authors.lastname: Shimizu
authors.forename: R
authors.initials: R
authors.lastname: Takeda
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Ibayashi
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D005877:Gigantism / Q000097:blood / Q000188:drug therapy*; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007564:Japan; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D015282:Octreotide / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide